Talk:Nimodipine

From Wikipedia, the free encyclopedia

	Nimodipine is part of WikiProject Pharmacology, a project to improve all Pharmacology-related articles. If you would like to help improve this and other pharmacology articles, please join the project. All interested editors are welcome.
Start	This article has been rated as start-Class on the quality scale.
Mid	This article has been rated as mid-importance for this Project's importance scale.

This was inserted:

"FDA ALERT [1/2006): The FDA has requested that Bayer add a boxed warning to the nimodipine (Nimotop) labeling to warn about medication administration errors with nimodipine. Nimodipine is approved for oral administration to improve neurological outcome after subarachnoid hemorrhage. When administered intravenously or parenterally, it can cause serious adverse events, including death. Nimodipine must not be administered intravenously or by any parenteral route." http://www.fda.gov/CDER/drug/InfoSheets/HCP/nimodipineHCP.htm Pqmos 07:56, 18 January 2007 (UTC)

I'll rephrase this a bit, but it sounds serious. I thought intravenous nimodipine was in use once upon a time. JFW | T@lk 14:53, 2 March 2007 (UTC)